Medulloblastoma and Down Syndrome: An Extremely Rare Association.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
received:
14
12
2021
accepted:
17
02
2022
pubmed:
16
6
2022
medline:
1
10
2022
entrez:
15
6
2022
Statut:
ppublish
Résumé
Medulloblastoma has a reduced incidence in Down syndrome (DS). This protective characteristic has not been clarified yet. Here, we report the second case of SHH medulloblastoma and DS documented in the literature. A complete surgery was performed followed by reduced craniospinal irradiation dose and adjuvant chemotherapy. No evidence of tumor recurrence was observed. The overall survival was 9.1 years. No family history or physical stigma of other hereditary predisposition syndrome was found. In the elucidation of this extremely rare association, future case reports play an important role in defining the spectrum of brain tumors and their peculiar features in DS.
Identifiants
pubmed: 35704799
doi: 10.1097/MPH.0000000000002448
pii: 00043426-202210000-00015
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
415-418Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Roizen NJ, Patterson D. Down’s syndrome. Lancet. 2003;361:1281–1289.
Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. Oncologist. 2009;14:164–173.
Shimada A. Profile of Down syndrome–associated malignancies: epidemiology, clinical features and therapeutic aspects. Pediatr Hematol Oncol J. 2021;6:63–72.
Bruwier A, Chantrain CF. Hematological disorders and leukemia in children with Down syndrome. Eur J Pediatr. 2012;171:1301–1307.
Nižetić D, Groet J. Tumorigenesis in Down’s syndrome: big lessons from a small chromosome. Nat Rev Cancer. 2012;2:721–732.
Satgé D, Stiller CA, Rutkowski S, et al. A very rare cancer in Down syndrome: medulloblastoma. Epidemiological data from 13 countries. J Neurooncol. 2013;112:107–114.
Gómez S, Garrido-Garcia A, Garcia-Gerique L, et al. Novel method for rapid molecular subgrouping of medulloblastoma. Clin Cancer Res. 2018;24:1355–1363.
Benesch M, Moser A, Sovinz P, et al. Medulloblastoma in a child with Down syndrome: long-term remission with multimodality treatment. Pediatr Blood Cancer. 2009;53:1150–1151.
Boni A, Ranalli M, Del Baldo G, et al. Medulloblastoma associated with Down syndrome: from a rare event leading to a pathogenic hypothesis. Diagnostics (Basel). 2021;11:254.
Mangum R, Varga E, Boué DR, et al. SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature. Childs Nerv Syst. 2016;32:2439–2446.
Holgado BL, Guerreiro Stucklin A, Garzia L, et al. Tailoring medulloblastoma treatment through genomics: making a change, one subgroup at a time. Annu Rev Genomics Hum Genet. 2017;18:143–166.
Baxter LL, Moran TH, Richtsmeier JT, et al. Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum Mol Genet. 2000;9:195–202.
Zorick TS, Mustacchi Z, Bando SY, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet. 2001;9:811–814.
Satgé D, Seidel MG. The pattern of malignancies in Down syndrome and its potential context with the immune system. Front Immunol. 2018;9:3058.
Grieco J, Pulsifer M, Seligsohn K, et al. Down syndrome: cognitive and behavioral functioning across the lifespan. Am J Med Genet C Semin Med Genet. 2015;169:135–149.
Hithersay R, Hamburg S, Knight B, et al. Cognitive decline and dementia in Down syndrome. Curr Opin Psychiatry. 2017;30:102–107.
Duffner PK, Cohen ME, Thomas P. Late effects of treatment on the intelligence of children with posterior fossa tumors. Cancer. 1983;51:233–237.
Segaran RC, Chan LY, Wang H, et al. Neuronal development-related miRNAs as biomarkers for Alzheimer’s disease, depression, schizophrenia and ionizing radiation exposure. Curr Med Chem. 2021;28:19–52.
Ashley DM, Merchant TE, Strother D, et al. Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children’s Oncology Group study P9934. J Clin Oncol. 2012;30:3181–3186.
Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013;14:1200–1207.
Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood. 2002;99:245–251.
Dufour C, Foulon S, Geoffray A, et al. Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5. Neuro Oncol. 2021;23:1163–1172.
Petrirena GJ, Masliah-Planchon J, Sala Q, et al. Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression. Oncotarget. 2018;9:10175–10183.
Kahalley LS, Peterson R, Ris MD, et al. Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma. J Clin Oncol. 2020;38:454–461.
Pereira V, Torrejon J, Kariyawasam D, et al. Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma. Neurooncol Adv. 2021;3:vdab097.
Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018;19:785–798.